Sylvia V. Alarcon

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

Arun Rajan, Ronan J. Kelly, Jane B. Trepel et al. · Clinical Cancer Research · 2011 · 140 citations · Full text

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

Andrea B. Apolo, Rosa Nadal, Yusuke Tomita et al. · The Lancet Oncology · 2020 · 88 citations · Full text

Urology, Genitourinary Cancer, Medicine +8

Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants

Thomas L. Prince, Toshiki Kijima, Manabu Tatokoro et al. · PLoS ONE · 2015 · 58 citations · Full text

Client Proteins, Drug Target, Protein Assembly +23

A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma

Andrea B. Apolo, Fatima Karzai, Jane B. Trepel et al. · Clinical Genitourinary Cancer · 2016 · 52 citations · Full text

Urology, Anti-endoglin Antibody, Genitourinary Cancer +5

A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas

Sook Ryun Park, Giovanna Speranza, Richard Piekarz et al. · Cancer Chemotherapy and Pharmacology · 2013 · 33 citations · Full text

Multi-histology Trial, Gastrointestinal Oncology, Medicine +10